Abstract: An evaluating method includes an evaluating step of evaluating a relative pharmacological action of a combination of an immune checkpoint inhibitor and an anticancer drug as a combination drug compared with a pharmacological action of an immune checkpoint inhibitor alone in a subject to be evaluated, using (i) a concentration value of at least one metabolite among Glu, Arg, Orn, Cit, His, Val, Phe, Tyr, Met, Pro, Asn, Leu, Lys, Thr, Ile, Gln, Ala, Ser, a-ABA, Trp, Gly, AnthA, hKyn, hTrp, Kyn, KynA, NP, QA, and XA in blood of the subject to be evaluated, or (ii) a value of a formula in the absence of use of an anticancer drug as a combination drug and a value of the formula in the presence of the use that are calculated using the concentration value and the formula including an explanatory variable to be substituted with the concentration value and an explanatory variable on the presence or absence of the use.

Abstract: Problem to be solved: An object of the present invention is to obtain medicinal effect that could not be obtained by conventional peptide vaccines that activate and proliferate a CD8-positive CTL by administering a Class II epitope as a peptide vaccine. Solution: The inventors of the present invention have found, as a result of diligent examination on the aforementioned problems, that these problems can be solved by acquiring a peptide having a partial amino acid sequence containing a mutated amino acid of a neoantigen expressed in cancer cells and being an epitope presented by a Class II molecule.

Abstract: The present application relates to an antigen peptide derived from the sequence of epidermal growth factor receptor having T790M point mutation and a pharmaceutical composition for the treatment of cancer comprising the peptide.

Abstract: The present application relates to an antigen peptide derived from the sequence of epidermal growth factor receptor having T790M point mutation and a pharmaceutical composition for the treatment of cancer comprising the peptide.

Abstract: The present application relates to an antigen peptide derived from the sequence of epidermal growth factor receptor having T790M point mutation and a pharmaceutical composition for the treatment of cancer comprising the peptide.

Abstract: Methods of thymic vaccination are described, in which a polypeptide of interest is administered and which allows positive or negative selection of a T cell receptor (TCR) specificity in the thymus, to retain a desired specificity (positive) or to eliminate an undesired specificity (negative) at the level of TCR repertoire development, in order to generate TCRs which are designed to recognize disease antigens or foreign antigens, such as to treat or prevent cancers, autoimmune diseases, infections, or effects of biological warfare agents.